|Treatments:||Chemotherapy||Hospital:||University of Turin|
This phase 2 study involved 18 patients with carcinoma in situ (CIS) of the bladder. The median patient age was 75 years and 88.8% were male.
Patients received chemotherapy with gemcitabine.
The most severe toxicities were grade 3 cystitis (bladder inflammation), pain, and leucopenia.
The median overall survival was 44 months.
Correspondence: Dr. Paolo Gontero; email: firstname.lastname@example.org